

Welcome to the 2024 Spring Forum!





Today's Agenda (details available online at forum.ncbch.net)

7:30 AM – Networking Breakfast 8:45 AM – Welcome and Introductions 9:00 AM - Legal Update 9:30 AM – Leapfrog Safety and Quality Update 10:00 AM – Innovative Savings Strategies 11:00 AM – Obesity and Diabetes Panel 12:00 PM – Innovations in Employer Benefits 12:30 PM – Networking Lunch 1:30 PM – Culture of Wellbeing Award 2:00 PM – Addressing Mental Health 3:00 PM – Wrap-up



Follow us on Social Media











facebook

Instagram







Legislative and Legal Update for Employers

Lindsey Sommers, J.D.

Principal Regulatory Resources Group Mercer





Health & Benefits Compliance Update

March 15, 2024

Lindsey Sommers, JD Principal and East Market MercerGUIDE Practice Lead, Mercer

A business of Marsh McLennan

welcome to brighter

1. Legislation, litigation, and regulation involving prescription drugs and PBMs

State regulation of PBMs Copay assistance programs

Rx as essential health benefits

2. Plan Management and Oversight Time for a plan management review Novel lawsuits over plan drug prices

3. Mental Health Parity – Ongoing enforcement and final rules

Third CMS/DOL Report to Congress anticipated MHPAEA – Awaiting final rules

4. Potpourri – Other developments to watch in 2024

RxDC submission of 2023 data

Expiration of telehealth relief for HDHPs

Upcoming agency guidance

Inflation Reduction Act's impact on Part D creditable coverage calculations

5. Resources

Legislation, litigation, and regulation involving prescription drugs and PBMs



Senate work to continue on its own healthcare package


PBM reforms in the Pharmacy Benefit Manager Reform Act (<u>S 1339</u>) target employer plans, passed by Senate HELP committee last June

- · Extensive new disclosures by PBMs to plan sponsors
- Require PBMs to pass through to health plans all rebates, fees, discounts and certain other remuneration
- · Commercial market ban on spread pricing
- Department of Labor study on whether PBMs should serve as ERISA fiduciaries to plans

PBM reforms affecting public programs (S 2973), passed by Senate Finance committee last December

- Delink list drug prices and PBM compensation in Medicare
- Require a study of how vertical integration in the pharmacy space is affecting Medicare drug costs and spending
- Ban spread pricing in Medicaid

States focused on lowering rising drug costs in 2024



Updated Feb. 12, 2024

Mercer

Common bill provisions

- 1. Mandated reimbursement levels for some plan components such as dispensing fees
- 2. Prohibition on steerage to pharmacies (mail-order or retail) affiliated with the PBM
- 3. Mandatory sharing of all/portion of rebates to participants at the point-of-sale
- 4. Ban Coupon maximizer/accumulator programs (Ex: Prudent or SaveOn) by requiring third-party assistance to apply to plan cost sharing (deductible/out-of-pocket maximum)
- 5. Insulin cost-sharing caps
- 6. Spread pricing ban
- 7. Other restrictions on specialty pharmacies
- 8. Canadian importation
- 9. Prohibition on reimbursement "clawbacks"/(Direct-indirect remuneration)

Drug manufacturer financial assistance programs

Must plans count such assistance towards a plan's deductible and out-of-pocket maximum?

2020 Notice of Benefit and Payment Parameters (NBPP) rule reinstated by court in HIV and Hepatitis Policy Inst. v. HHS

2020 NBPP appears to require plans to accumulate drug manufacturer financial assistance to a plan's cost-sharing limits, *unless* the drug has a medically appropriate generic equivalent.

The rule's <u>preamble</u> (p. 17545) states: "... the final regulation limits the discretion to exclude manufacturer coupons from counting towards the annual limitation on cost sharing for specific prescription brand drugs that have a generic equivalent...Where there is no generic equivalent available or medically appropriate...amounts paid toward cost sharing using any form of direct support offered by drug manufacturers must be counted toward the annual limitation on cost sharing. We have added language to the regulation text to address this clarification."

The <u>regulation text</u> states: "...Notwithstanding any other provision of this section, and to the extent consistent with state law, amounts paid toward cost sharing using any form of direct support offered by drug manufacturers to enrollees to reduce or eliminate immediate out-of-pocket costs for specific prescription brand drugs that have an available and medically appropriate generic equivalent are not required to be counted toward the annual limitation on cost sharing ..."

New rules expected to address whether drug manufacturer financial assistance is "cost-sharing."

HHS informed the court that in the interim HHS does not intend to take **enforcement action** against plans/issuers that don't count drug manufacturer financial assistance towards a participant's deductible and out-of-pocket maximum

Implications for HDHPs

Counting drug manufacturer financial assistance toward deductibles creates a compliance issue for HSA-qualifying HDHPs, as the agencies acknowledged in the <u>2021 NBPP</u> and <u>ACA FAQs Part 40</u>.

Mercer

Prescription drugs as essential health benefits

Implication of proposed changes

Proposed <u>2025 Notice of Benefit and Payment Parameters</u> clarifies that prescription drugs beyond a state's benchmark plan are usually essential health benefits (EHBs).

To the extent that a health plan covers drugs, in any circumstance, in excess of the benchmark, these drugs would be considered an EHB and would be required to count towards the annual limitation on cost sharing. This policy would apply unless the coverage of the drug is mandated by State action... Proposal could jeopardize copay maximizer/accumulator programs that rely on reclassifying prescription drugs covered by a health plan as non-EHBs (and not counting amounts paid for such drugs towards the outof-pocket maximum).

HHS is also <u>seeking input</u> on changing the EHB prescription drug standard from the US Pharmacopeia (USP) Medicare Model Guidelines (MMG) to the USP Drug Classification (DC) system, which would result in the reclassification of fertility and anti-obesity medications (among others) as EHBs.

Plan Management and Oversight




Recent developments may heighten fiduciary risk for ERISA plan sponsors

While fiduciary risks for plan sponsors are not new, health plan transparency requirements, high profile lawsuits, and an increase in DOL health plan audit activity, may heighten fiduciary risk for ERISA plan sponsors.

Now is an ideal time to reassess fiduciary roles, responsibilities, and how to manage risk.





Mercer

Novel lawsuit related to group health plan drug prices

Lewandowski v. Johnson & Johnson, No. 1:24-cv-00671 (Feb. 5, 2024)

Lawsuit alleges large, self-funded health plan fiduciaries failed to <u>prudently manage</u> their prescription drug benefits plan, causing the ERISA plan and its members to overpay for benefits (higher prescription drug costs, premiums, deductible, coinsure and copays).

Plaintiff alleges **plan fiduciaries** caused overpayments for specialty drugs by:

- imprudently managing specialty drugs, especially generics
- steering members to mail, where prices were allegedly higher than retail for the generic specialty drugs
- failing to disincentivize use of brand drugs over lower-priced generics
- failing to engage in a prudent and reasoned decision-making process
- failing to adequately negotiate the contract with their PBM, and failing to prudently exercise their rights under the contract
- failing to adequately consider contracting with other PBMs, including pass-through PBMs
- failing to adequately consider carving out specialty drugs.

Takeaways

- Allegations in a complaint should not be taken as fact unless or until proven true.
- This case may be the first of a new genre of ERISA class actions where employees sue over the cost of health plan benefits.

Precautions

- Consider tracking case developments including defendants' response – with counsel.
- Consider adding standard language to SPDs disclosing that lower cost drugs may be available outside the prescription drug plan, including through coupon programs, manufacturer assistance programs, charities, or otherwise.
 - Keep in mind that processing prescription drug claims outside the PBM benefit will bypass built-in safety edits for drug-drug and drug-disease interaction checks.

It's a great time for a plan management review

Reassess fiduciary

Ensure governance is up to date – fiduciary roles, responsibilities, delegations and processes.

Review the fiduciary insurance policy to make sure it is appropriate.



Document steps taken to meet fiduciary duties.

Update plan documents and communications as needed.



Ensure timely compliance with ERISA's reporting and disclosure requirements.

Examples include, Form 5500, written MHPAEA comparative analysis and the annual gag clause attestation.

Focus on service providers

Select and monitor service providers based on their qualifications, quality of services, and compensation.

Service providers should mitigate cybersecurity risks and make plan data available when required or requested.

Analyze plan

Understand how increased plan costs affect participants.

Prepare to analyze those costs, as well as plan operations, using newly available transparency data.

Mo
enf

Monitor litigation and enforcement


Track lawsuits and DOL enforcement efforts.

Some recent cases concern service provider fees (including "hidden" fees), cross plan-offsetting and plan failures to obtain data from service providers.

Mercer

Reassess fiduciary duties and revisit strategies to manage risk

Employer actions taken to better meet health plan fiduciary responsibilities



Mercer Source: 10-minute survey on Health policy and employer health plans; based on respondents with 500 or more employees, n=220

16

Mental Health Parity – Ongoing enforcement and final rules



Spotlight on mental health benefits

- The need for behavioral health care remains elevated post-pandemic.*
- 76% of large employers that responded to <u>Mercer's National Survey</u> say that improving access to behavioral healthcare will be a priority over the next few years.
- Enforcement of the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) continues to be a high priority for federal agencies.
- Individual and class action lawsuits continue to challenge behavioral health benefit denials.
- Sweeping changes to the MHPAEA rules have been proposed for 2025.

...the Department of Labor has dedicated an unprecedented amount of time and resources to bringing health plans into compliance with mental health parity


-Lisa Gomez, Asst. Secretary of Labor, Aug. 7, 2023 <u>blog</u>

*Kaiser Family Foundation, <u>Mental health and</u> <u>substance use state fact sheets</u>

Copyright © 2024 Mercer Health & Benefits LLC. All rights reserved

Other enforcement and litigation

- 2022 MHPAEA Enforcement <u>Fact Sheet</u> details agency enforcement efforts beyond the NQTL comparative analysis review
 - DOL cited 20 MHPAEA violations in 11 investigations (CMS cited 7)
 - Violations included impermissible visit limits on nutritional counseling, higher copays for in-network outpatient MH/SUD benefits, and separate treatment limits for ABA therapy for autism
- · Private litigation continues against plans and their service providers
 - Class actions and individual plaintiffs
 - Generally challenging coverage denials for residential treatment, wilderness therapy, and treatments for autism spectrum disorder



Copyright © 2024 Mercer Health & Benefits LLC. All rights reserved

Proposed MHPAEA rule

Departments propose sweeping changes to improve access to MH/SUD care, in-network providers

- Significant changes to NQTL analysis include:
 - New three-part NQTL framework includes numerical testing and mandatory data collection and analysis, with certain exceptions available; specific focus on network composition NQTLs
 - Numerous examples illustrate compliant/noncompliant NQTLs
 - Codifies written comparative analysis requirements, includes new fiduciary certification
- "Meaningful benefit" standard introduced
- Incorporates end of MHPAEA opt-out for nonfederal government plans

If finalized, effective for 2025 plan year and increased access is likely to result in cost increases.

As a result of these proposals, the Departments anticipate changes in network composition and medical management techniques that would result in more robust mental health and substance use disorder provider networks and fewer and less restrictive prior authorization requirements for individuals seeking mental health and substance use disorder treatment.

MHPAEA – Awaiting final rules

No date <u>from DOL</u> for final action; June 2024 <u>according to IRS</u>

Sample excerpts from <u>9,500+ stakeholder comments</u>

Plan sponsors	Insurers	Patients	Providers
 "[T]he various tests and requirements in the proposed regulations (in particular, the 'substantially all test,' 'predominant test,' and the 'relevant data and evaluation requirement') are wholly unworkable" <u>ERIC</u> (the ERISA Industry Committee) "[O]ur members are concerned that plans and issuers could be forced to choose between accepting lower quality providers into networks, which could compromise outcomes and patient safety, or retain existing quality standards and be out of compliance." <u>American Benefits Council</u> 	 "The proposed regulations have significant legal, policy, and operational flaws and should not be finalized. Perhaps more importantly, the proposed rules will not achieve the goals of increasing access to mental health care or substance use disorder treatment." <u>AHIP</u> (America's Health Insurance Providers) 	 "We are particularly supportive of the requirement that insurers and health plans collect data and evaluate it for differences in outcomes for MH/SUD relative to M/S." "We strongly oppose the exceptions proposed in this rule for 'independent professional medical or clinical standards' and for 'waste, fraud and abuse." <u>Cystic Fibrosis Foundation</u> 	 "The AHA applauds the Administration for proposing these clear and specific provisions to improve oversight of MHPAEA[T]his rule will further close coverage loopholes and help ensure that patients can access the care they need." <u>American Hospital Association</u>

Potpourri – Other developments to watch in 2024



Upcoming Developments

RxDC submission due June 1

- Updated instructions recently released
- Aggregation restriction applies
- No good faith compliance relief
- Deadline to submit falls on a Saturday and no weekend rule applies – work with vendors to ensure all filings submitted no later than Friday, May 31



- Awaiting guidance that clarifies how plans determine Medicare Part D creditable coverage status determinations
- IRA includes enhancements that significantly increase the actuarial value of standard Part D coverage in 2025, leading to concerns that achieving creditable coverage status could be harder for group health plans (particularly HDHPs)



- Current relief for HDHPs offering telehealth below the statutory minimum high deductible expires Dec. 31, 2024 for calendar year plans and during 2025 for noncalendar year plans
- Congress considering legislation to permanently allow HDHPs with HSAs to cover telehealth/remote care on a pre- or no-deductible basis, but no action yet

Upcoming agency guidance could include...

Final rules addressing:

- MHPAEA
- Independent dispute resolution (IDR)
 operations
- Moral/religious exemptions to certain preventive services under the ACA preventive care mandate
- **Nondiscrimination** in health programs and activities (i.e., **section 1557**)
- HIPAA privacy requirements for reproductive healthcare
- Hospital or other fixed indemnity insurance as excepted benefits, tax treatment
- 2025 Notice of Benefit and Payment Parameters

Proposed rules addressing:

- Additional transparency requirements (e.g., air ambulance reporting, agent and broker disclosures, and provider enforcement)
- Cybersecurity modifications to the HIPAA security rule
- Provider nondiscrimination
 requirements
- Contributions to and benefits from paid family and medical leave programs
- Nondiscrimination for confidentiality of substance use disorder patient records

Expecting subregulatory guidance, including:

- Updated MHPAEA
 self-compliance tool
- Implementation guidance about Rx MRFs
- Part D redesign program instructions; impact on creditable coverage determinations

Currently under review at Office of Management and Budget


Mercer





Law & Policy resources on mercer.com


- Practice of prior authorization draws increased scrutiny (Feb. 29, 2024)
- IVF uncertainty in Alabama: What can employers do? (Feb. 29, 2023)
- Roundup: Employer resources on DOL's final independent contractor rule (Feb. 26, 2024)
- Reviewing San Francisco contractor-lessee health plan, pay rules (Feb. 22, 2024)
- Mercer projects 2025 HSA, HDHP and excepted-benefit HRA figures (Feb. 16, 2024)
- <u>New RxDC reporting instructions: Headaches or opportunities?</u> (Feb. 15, 2024)
- <u>Summary of 2024 benefit-related cost-of-living adjustments</u> (Feb. 8, 2024)
- Paid family and medical leave snapshots across the US (slide deck) (Feb. 6, 2024)
- Roundup of selected state health developments, fourth-quarter 2023 (Feb. 5, 2024)
- As virtual care becomes more clinical, there are more rules to follow (Feb. 1, 2024)
- <u>2024 state paid family and medical leave contributions and benefits</u> (Jan. 31, 2024)
- What to expect from the states in 2024 (Jan. 25, 2024)
- <u>The practical impact of Florida drug importation from Canada</u> (Jan. 18, 2024)
- <u>2024 federal poverty levels can impact ESR affordability</u> (Jan. 17, 2024)



Mercer

Law & Policy resources on mercer.com (cont'd.)

- 2024 quick benefit facts (Jan. 15, 2024)
- DOL sets 2024 penalties for health and welfare benefit plan violations (Jan. 11, 2024)
- <u>Make cybersecurity part of your 2024 New Year's resolutions</u> (Jan. 4, 2024)
- New York announces 2024 HCRA covered-lives assessment rates (Jan. 3, 2024)
- House passes package of PBM, price transparency, billing reforms (Dec. 14, 2023)
- Employers weigh start of RSV immunization coverage (Dec. 14, 2023)
- Some states require group health plan sponsor reporting (Dec. 11, 2023)
- Moving targets: Rx legislative activity to watch in 2024 (Dec. 7, 2023)
- Lifestyle spending accounts offer flexibility, personalization (Dec. 7, 2023)
- <u>What plan sponsors should know about DOL's new fiduciary proposal</u> (Dec. 6, 2023)
- ERISA plan sponsors are responding to heightened fiduciary risk (Nov. 22, 2023)
- Broad coalition urges Senate action on PBM reforms (Nov. 16, 2023)
- Roundup of selected state health developments, third-quarter 2023 (Nov. 15, 2023)





Mercer is not an "administrator," "sponsor" or other "fiduciary" within the meaning under applicable law, including the Employee Retirement Income Security Act of 1974, as amended.

Mercer is not engaged in the practice of law, and the content is not intended as a substitute for legal advice. Accordingly, you should secure the advice of competent legal counsel with respect to any legal matters related to this document or the content.

Mercer is not engaged in the practice of medicine and the content herein is not intended as a substitute for medical advice.

Mercer and its affiliates make no representations whatsoever about any third party website that you may access through this document. By including links to such websites in this document, Mercer and its affiliates do not endorse or accept any responsibility for such websites' content or use or indicate that Mercer or its affiliates are affiliated in any way with such websites' owner. Mercer and its affiliates do not investigate, verify, monitor, or endorse such websites. In addition, the access to such third party websites through this document does not imply that Mercer and its affiliates are affiliated with or otherwise endorse any third parties, that Mercer and its affiliates are legally authorized to use any trademark, trade name, logo, or copyright symbol displayed in or accessible through the links, or that any linked site is authorized to use any trademark, trade name, logo, or copyright symbol of Mercer or its affiliates.

A business of Marsh McLennan

Copyright © 2024 Mercer (US) LLC. All rights reserved.

Hospital Safety & Quality Update



Jill Berger

Director of Employer and Payor Relations The Leapfrog Group



The North Carolina Business Coalition on Health

March 2024



OIG report found 1 in 4 Medicare Patients Harmed





© The Leapfrog Group 2024 31

Bank of America Stadium has a capacity of 74,867





3rd leading cause of death




The cost





Eappen S, Lane BH, Rosenberg B, et al. Relationship Between Occurrence of Surgical Complications and Hospital Finances. *JAMA*. 2013;309(15):1599-1606. doi:10.1001/jama.2013.2773.









PURCHASERS



Leapfrog: The Employer Voice

- Founded by purchasers in 2000 in response to 1999 IOM Report *To Err is Human*
- Premier purchaser-driven nonprofit for safety and transparency—and structuring payment to reward excellence
- Our mission: Giant Leaps for Patient Safety
- Collects and publicly reports hospital and ASC quality and safety
- Gold standard for health care transparency





Regional Leaders: The Heart and Soul of Leapfrog









Who Submits Data?

- Nationally, over 64% of hospitals (more than 2,200) participate in the Leapfrog Hospital Survey, representing 73% of U.S. hospital beds
- North Carolina has 91% of hospitals participating!

Data is publicly reported by hospital and used by national health plans, many publishers



© The Leapfrog Group 2024

Why 2,200+ Hospitals and ASCs Submit Data

By participating in the Leapfrog Hospital Survey, hospitals can:

- Respond to requests of purchasers
- Benchmark performance
- Galvanize improvement through transparency
- Predict their status in value-based purchasing programs (i.e., CMS, health plans, etc.)
- Offer more comprehensive information for use in the Hospital Safety Grade



Novant Health Presbyterian Medical Center

Maternity Care

materinty ourc			
Measure name	Leapfrog's Standard	Hospital's Progress	
High-Risk Deliveries	Hospitals should deliver at least 50 very-low birth weight babies per year OR the hospital must maintain a lower-than-average morbidity/mortality rate for very-low birth weight babies.	ACHIEVED THE STANDARD	
	▼ SHOW MORE ON THIS HOSPITAL'S PERFORMANCE ▼		
Cesarean Sections	This is defined as first-time mothers giving birth to a single baby, at full-term, in the head-down position who deliver their babies through a C-section. Hospitals should have a rate of C-sections of 23.6% or less.	ACHIEVED THE STANDARD	
	▼ SHOW MORE ON THIS HOSPITAL'S PERFORMANCE ▼		
Early Elective Deliveries	This is defined as mothers being scheduled for cesarean sections or medication inductions prior to 39 weeks gestation without a medical reason. Hospitals should have a rate of early elective deliveries of 5% or less.	ACHIEVED THE STANDARD	
	▼ SHOW MORE ON THIS HOSPITAL'S PERFORI		
Episiotomies	This is defined as mothers having an incision made in the perineum (the birth canal) during childbirth. Hospitals should have a rate of episiotomies of 5% or less.	ACHIEVED THE STANDARD	
	▼ SHOW MORE ON THIS HOSPITAL'S PERFORM	MANCE -	
Screening Newborns for Jaundice Before Discharge	Hospitals should screen at least 90% of babies for jaundice.	ACHIEVED THE STANDARD	



New This Year

Number of Live Births	The hospital had 6,030 live births (i.e., liveborn infants) at this hospital location for the reporting time period.	
Midwives	This hospital does have certified nurse-midwives and/or certified midwives deliver newborns.	
Doulas	This hospital allows patients to bring their own doulas.	
Lactation Services	This hospital offers lactation services in the hospital and outpatient setting.	
Vaginal Delivery After Cesarean Section (VBAC)	This hospital does offer vaginal delivery after cesarean section (VBAC).	
Tubal Ligation	This hospital does offer tubal ligation during the labor and delivery admission.	



Health Equity

"Even when admitted to the same hospital, Black patients experience **higher rates of hospital-acquired injuries or illnesses** occurring during or shortly after surgical procedures relative to white patients"





Racial, Ethnic, and Payer Disparities in Adverse Safety Events: Are there Differences across Leapfrog Hospital Safety Grades?



Without Leapfrog, we don't know about...

Maternity care

• C-section rate, early elective deliveries, episiotomies, high-risk deliveries, and maternity care processes

Hospital policy on Never Events

Bar code medication administration

Pediatric care

 Patient experience of children and their parents (CAHPS Child Hospital Survey) and radiation doses

Inpatient Surgery

• Volume of high-risk procedures and appropriateness of care policies



© The Leapfrog Group 2024

Leapfrog ASC Survey

- Compare ASCs and hospital outpatient departments
- Collect data and publicly report on information that is of particular interest to employers, purchasers, and consumers
- Keep the reporting burden as low as possible
- Alignment with other performance measurement groups
- Include cutting-edge measures not publicly reported by any other national organization
- Maintain consistent measurement structure for benchmarking and quality improvement



Leapfrog Safety Grade

- 28 measures of **patient safety only** (errors, injuries, accidents, and infections)
- Updated every 6 months (Fall and Spring)
- Assigned to over 2,600 general acute-care hospitals
- Methodology advised by National Expert Panel & monitored for validity and reliability by faculty at Johns Hopkins Medicine







Charlotte, NC





How Does North Carolina Rate?

States by A Grade Rate on the Leapfrog Hospital Safety Grade

Fall 2023			Spring 2023	
Ranking	State	% "A" Hospitals	Ranking	% "A" Hospitals
1	Utah	51.9%	3	48.1%
2	Virginia	50.7%	9	38.6%
3	North Carolina	47.7%	6	42.0%
4	Pennsylvania	44.1%	4	46.5%
5	South Carolina	43.1%	7	41.2%



Novant Health Presbyterian Medical Center

Infections		ems with rgery V	Safety Problems		s to Prevent v
			1		
MRSA Infection	C. diff Infection	Infection in the blood	Infection in the urinary tract	Surgical site infection after colon surgery	Sepsis infection after surgery

Hospital Performs Worse Than Average 🔤 Better Than Average


This Hospital's Score: 0.894 Best Hospital's Score: 0.000 Average Hospital's Score:	MRSA infection Staph bacteria are common in hospitals, but Methicillin- resistant Staphylococcus aureus (MRSA) is a type of staph bacteria that is resistant to (cannot be killed by) many antibiotics. MRSA can be found in bed linens or medical equipment and can be spread if providers do not properly wash their hands between patients. MRSA can cause life-threatening bloodstream infections, pneumonia and surgical site infections.	What safer hospitals do: Doctors and nurses should clean their hands afte every patient. Hospital rooms and medical equipr thoroughly cleaned often. Safer hospitals will als- patients separate from other patients and require visitors to wear gloves and gowns around these p
0.927 Worst Hospital's Score: 3.653	This number represents a comparison of the number of infections that actually happened at this hospital to the number of infections expected for this hospital, given the number of patients they care for on a daily basis and how widespread MRSA infection is in their local community. A number lower than one means fewer infections than expected; a number more than one means more infections than expected. For details on sources, click here.	



The road ahead in health care







Patients Come First. No compromise.





Errors Are Easy



Missed a dose

Missed the lab test report

Didn't have time to wash hands

Forgot something

Gave it to the wrong patient

Didn't tell the nurse to watch for that

Patient fell

Left a sponge in

Distracted, very busy

Etc etc etc...

54

Leapfrog Hospital Survey Sections

1. Ethics

- Billing Ethics
- Health Equity
- Patient Consent
- 2. Medication Safety CPOE
- **3.** Inpatient Surgery
 - Hospital and Surgeon Volume
 - Surgical Appropriateness
- 4. Maternity Care
 - Maternity Care Volume
 - Early Elective Deliveries
 - Cesarean Birth
 - Episiotomy
 - Process Measures of Quality
 - High-Risk Deliveries
- 5. ICU Physician Staffing (IPS)



6. Patient Safety Practices

- Culture of Safety Leadership Structures and Systems
- Culture Measurement, Feedback, and Intervention
- Nursing Workforce
- Hand Hygiene
- Nurse Staffing Skill Level
- 7. Managing Serious Errors
 - The Leapfrog Group "Never Events" Policy Statement
 - Healthcare-Associated Infections
- 8. Medication Safety
 - Barcode Medication Administration
 - Medication Reconciliation
 - Opioid Prescribing
- 9. Pediatric Care
 - Patient Experience
 - Pediatric Computed Tomography Radiation Dose
- **10.** Outpatient Procedures
 - Basic Information of Outpatient Department
 - Medical. Surgical, and Clinical Staff
 - Volume and Safety of Procedures
 - Medication Safety for Outpatient Procedures
 - Patient Experience

Leapfrog's Never Events Policy: Ethical Principles



Never events are extremely rare medical errors that should never happen to a patient, such as surgery performed on the wrong body part or leaving a foreign object inside a patient after surgery.

A hospital "fully meets" Leapfrog's standard if they agree to all of the following if a Never Event occurs within their facility:

- Apologize to the patient and family
- Waive all costs related to the event
- **Report** the event to an external agency and conduct a **rootcause analysis**
- Interview patients and families and inform them of action(s) hospital will take
- Provide support for caregivers
- Ensure compliance and make this policy available to patients



79% hospitals fully met Leapfrog's standard in 2022



This is personal.



The Judie Burrows Education Institute

The Judie Burrows Education Institute is the educational arm of The Leapfrog Group and officially launched in March of 2022. The Institute will equip people to hit the accelerator and make change:

• Employers and other purchasers, who use Leapfrog data to drive for the best care for their employees;

• Health care leaders, clinicians, and business leaders who need to work together to achieve improvements for patients;

• All of us, whether we have been a patient or not, because we need information on how to find the best care and advocate for our loved ones.








The future of technology is really about patient safety.



Generative AI


Bad ideas



Good Ideas








Transparency is the indispensable force.






It's often mandatory.

STAT

New price transparency regulations for hospitals, insurers empower patients

By Seema Verma and Aneesh Chopra July 22, 2022



FROM

The Consolidated Appropriations Act

Forbes

This Federal Law Will Completely Overhaul Company Health Benefits. Nobody Is Ready.



Compliance involves extensive new rules and responsibilities, including:

- Removal of contract gag clauses
- Access to claims and data
- Price transparency
- Disclosure of direct and indirect compensation
- Mental health and substance use disorder parity
- Employer is accountable for value

Hospitals Know




St. Bernard Hospital, an important safety net hospital in South Chicago

Comparing pre-pandemic and post-pandemic data, the hospital saw:

- 100% REDUCTION in CLABSI and CAUTI
- 72% REDUCTION in MRSA
- Improvements across the Board

Transparency Galvanizes; Early Elective Deliveries



Transparency is indispensable


DIVE BRIEF

Hospital adverse event rates decline over a decade, JAMA study finds

Published July 12, 2022 Study analyzed data from # of events per 1000 discharges 2010-2019 200 150 100 50 0 AMI Heart Failure Major Surgery All Other Pneumonia Conditions Adverse events by type The Leapfrog Group 2022

2010

2019



Patients come first. No compromise.





Employers Can Champion Patients.



- Commit to transparency in all contracts, with all third parties (PBMs, consultants, TPAs, etc)
- Insist on campaign for transparency
- Give employees as much information as possible to make decisions about their care. Use Leapfrog to help.
- Push for 100% participation in Leapfrog Hospital Survey & Leapfrog ASC Survey
- Use the data in purchasing, contracting, public reporting

All roads true north.

- Patients come first. No compromise.
- This is personal.
- The future of technology is really about patients.
- Transparency is the indispensable force for change. It's about patients.
- Patients come first. No compromise.





Appendix



5 Step Verification

Leapfrog has several protocols in place to verify the accuracy of our results, including:

- Affirmation of Accuracy
- Warnings in the Online Survey Tool
- Extensive Monthly Data Verification
- Monthly Documentation Requirements
- On-Site Data Verification



Medical and Rx Innovative Savings Strategies





Medical Savings by Traveling

William Howard

Senior Vice President, Bernhardt Furniture Company

> Rajesh Rao CEO IndusHealth

Chad Adams

Senior Executive/Strategic Development IndusHealth



INDUS HEALTH **GLOBAL HEALTHCARE OPTIONS**

WHERE WE ARE

 Premiums for employer plans climbed roughly 7% in 2023 and over 8% for 2024 to reach \$24k for family plans and nearly \$8.5k for individuals according to Kaiser Family Foundation (KFF)





THE leader in the corporate medical travel industry

WHAT IS INDUSHEALTH?



Serves self-insured employers w/100 to over 30,000 employees in size



19 years of proven experience

HOW THE PROGRAM WORKS

- Plan bolted on to existing plan at zero cost
- Benefit available to employees and families covered
- Employees internally informed about plan
- Employee contacts Indus when procedure needed
- Case manager assigned
- Simplified billing and reporting






WORKS FOR EMPLOYEES



100% optional, NO deductible, NO bills





2nd opinion prevents incorrect/unnecessary surgeries



Cash incentives based on shared savings Companion travel included

Return to work quicker with less pain

BENEFITS AND RESULTS

- Cost savings from around ~\$20k to over \$100k per procedure
- Annual cost savings >\$250k per 1,000 employees
- Annual costs savings up to \$800k when including pharma
- Reduces stop-loss and workers comp claims
- No monthly fees
- Proven and time-tested risk mitigations strategies





SURGICAL SAVINGS

Procedure	Package Cost Range		
Total Knee Replacement	\$19K - \$26K		
Total Hip Replacement	\$20K - \$27K		
Rotator Cuff Repair	\$13K - \$18K		
Gastric Bypass	\$19K - \$25K		
Gastric Sleeve	\$17K - \$23K		
Hernia Repair	\$13K - \$17K		
Lumbar Fusion	\$24K - \$33K		
Cervical Disc Replacement	\$26K - \$39K		
Hysterectomy	\$14K - \$20K		

Average net savings of \$20K-\$25K per surgery

NOTE: Package costs are all-inclusive and can vary depending on destinations, procedure variations, and travel/stay related expenses incurred

HE ALTH

PHARMACEUTICAL SAVINGS

Specialty Rx	Annual Savings
Actemra	\$31K
Cosentyx	\$30K
Enbrel	\$26K
Epclusa	\$27K
Humira	\$27K
Humira (High Dose)	\$64K
Ocrevus	\$15K
Orencia	\$17K
Rituxan	\$18K
Stelara	\$33K
Stelara (High Dose)	\$146K
Viekira Pak	\$26K
and more	

NOTE: Package costs are all-inclusive and can vary depending on destinations, procedure variations, and travel/stay related expenses incurred

Annual net savings of \$400K-\$800K

INDUS HEALTH

INDUS HEALTH **GLOBAL HEALTHCARE OPTIONS**

Innovative Strategies for Pharmacy Spend

Jason Sorrells

Rx Sales Director Healthcare Bluebook





Locked into your PBM contract ...what can you do to help your plan and your members save \$?



Agenda



Understanding your existing PBM contract



Maximizing opportunities within existing PBM contract



Savings opportunities outside of PBM



Next Steps



Understanding your existing PBM contract

Understand your existing pharmacy contract

Ask your consultant to help you understand the critical components of your contract



- Identify specific Exclusions and understand how they are impacting your plan
- Know Drug definitions can significantly impact contract performance
- ✓ When are you allowed a Market Check to improve outdated contract terms
- Ensure your broker/consultant completes annual Reconciliation of contract guarantees

Example Contract Reconciliation

Discounts

Ingredient						
Channel	Claim Count	AWP	Cost	Guarantee	Achieved	Shortfall/Surplus
Retail 30 Brand	2,609	\$2,447,160	\$1,973,390	17.50%	19.36%	\$45,517
Retail 30 Generic	9,456	\$2,347,496	\$405,178	84.00%	82.74%	(\$29,578)
Retail 90 Brand	260	\$336,177	\$262,285	21.25%	21.98%	\$2,454
Retail 90 Generic	1,296	\$513,956	\$74,883	87.40%	85.43%	(\$10,125)
Mail Brand	17	\$21,981	\$17,154	21.25%	21.96%	\$156
Mail Generic	89	\$33,138	\$3,990	85.40%	87.96%	\$848
Specialty	298	\$1,870,757	\$1,486,691	20.25%	20.53%	\$5,238
TOTAL	14,026	\$7,570,664	\$4,223,570			(\$39,703)

Dispensing Fees

Channel	Claim Count	Dispensing	Guarantee	Achieved	Shortfall/Surplus
Retail 30 Brand	2,609	\$2,217	\$0.70	\$0.85	(\$391)
Retail 30 Generic	9,456	\$5,296	\$0.70	\$0.56	\$1,324
Retail 90 Brand	260	\$169	\$0.70	\$0.65	\$13
Retail 90 Generic	1,296	\$739	\$0.70	\$0.57	\$168
Mail Brand	17	\$0	\$0.00	\$0.00	\$0
Mail Generic	89	\$0	\$0.00	\$0.00	\$0
Specialty	298	\$45	\$0.00	\$0.15	(\$45)
TOTAL	14,026	\$8,465			(\$436)

Rebates				
		Total	Total	
Channel	Claim Count	Guarantee	Received	Shortfall/Surplus
Retail 30 Brand	2,169	\$520,560	\$507,641	(\$12,919)
Retail 90 Brand	185	\$134,125	\$137,236	\$3,111
Mail Brand	13	\$9,425	\$9,498	\$73
Specialty	185	\$407,000	\$382,103	(\$24,897)
TOTAL	2,552	\$1,071,110	\$1,036,478	(\$37,816)

Complete **RECONCILIATION** of annual performance with pharmacy contract guarantees


- ✓ Claim level
- ✓ \$ for \$ reimbursement
- ✓ No 'off setting'

Maximizing opportunities within your existing PBM contract

Additional PBM programs available to consider?

- **Coupon Maximizer Programs** •
 - PrudentRx (CVS) ٠
 - SaveOnSP (ESI)
 - Variable Copay (Optum) •
- **Copay Accumulator Program**

Copay Accumulator Adjustment and Copay Maximizers, Prevalence and Use in Commercial Insurance, 2018 to 2023



Source: Drug Channels Institute analysis of MMIT data; Drug Channels Institute estimates. Sample for 2018 includes 49 PBMs and payers representing 147 million commercially insured covered lives. Sample for 2020 includes 35 PBMs and payers representing 121.5 million commercially insured covered lives. Sample for 2023 includes 35 PBMs and pavers representing 117.8 million commercially insured covered lives.

Source: Drug Channels Institute research. This chart appears as Exhibit 143 in The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

DRUG CHANNELS INSTITUTE An HMP Global Company




92

Savings opportunities for plan and members outside of PBM

Rx costs continue to rise – what can employers and members do to help curb costs?

Hospital Care vs Prescription Drugs



Hospital Care Outpatient Rx drugs

Member out-of-pocket pharmacy spending is significantly higher (60%) compared to OOP medical spending

Patients pay for a greater share of the cost due to Rx plan designs and growth of coinsurance arrangements for pharmacy

Higher list prices drive higher rebate values

Most plan sponsors use rebates to offset premiums, but member's OOP is still increasing

*Outpatient Rx figures exclude inpatient Rx drug spending within hospitals and nearly all provider-administered outpatient drugs

Source: Drug Channels Institute analysis of National Health Expenditure Accounts, 2023



Mark Cuban Cost Plus Pharmacy

Cost Plus Drugs Team Cuban Card

Cost Plus Drugs is Now Available at Your Local Pharmacy

Sign up for Team Cuban Card to get our low drug prices at...

 Kroger
 meijer
 Alto-Vanadev
 Bakers
 City Market
 Differ
 Fred Meyer

 frugs
 Gerber
 Maria
 Maria
 Maria
 Metro
 Poly Less market
 Poly Less

 Pick'n Save
 Open
 Maria
 Smiths
 MB
 Mainline PHARMA©Y


 Muccare
 Open
 Maria
 Open
 Mainline PHARMA©Y

...and many independent pharmacies!



How does it work?

How the Team Cuban Card Works





MCCPP Savings Examples

Generic Lipitor

We think you should know how much your medications cost and why. A 90 count supply of 10mg Atorvastatin will cost: Your drug cost with us \$6.80 You save \$158.80 on your medication Retail price at other pharmacies \$165.60 Your final cost will include shipping and taxes, which vary by location. Manufacturing 15% Markup Pharmacy Labor \$0.90 \$0.90 \$5.00 11 *Additional cost at checkout Standard Shipping \$5.00 Learn more about our drug costs

<u>Generic Truvada</u>



S Healthcare Bluebook.

Integrated Health Management (340b program) Improved Care, Lower Costs

\$0 patient out-of-pocket cost Enhanced care management through our pharmacy team and providers

Improve outcomes for patients with diabetes and specialty drug needs Savings average from 45-75% on the cost of care and treatment

MAKO

Implement IHM at anytime, MakoRx will work with the Employer and existing PBM to carve out the medications covered by IHM and provide immediate savings without the hassle of switching PBMs. Conditions include: Diabetes, Migraine, Blood Thinner, COPD, Mental Health and Specialty Meds.

Integrated Health Management (IHM)

Treating chronic conditions can require expensive medications that significantly impact both patient and employer costs.

MakoRx created our Integrated Health Management programs to capitate and control ever-increasing chronic conditions costs by bundling care and medication into a fixed monthly cost per employee. **Diabetes Bundle:** One of the most prevalent and costly conditions on any health plan is diabetes care. Between the popularity of GLP-1 medications like Ozempic® or Mounjaro® and the cost of branded drugs and insulins, employers can significantly reduce health costs associated with diabetes by moving to a bundled care model. IHM provides all the testing, supplies, medications, virtual doctor visits and care team management for your participants with diabetes for the following costs:

MAKORX

IHM Diabetes Bundle	Average Per Patient Monthly Plan Spend	MakoRx Per Patient Monthly Pricing	Average Per Patient Monthly Savings
Standard Diabetes Bundle	\$783	\$295	\$488
Standard Ozempic	\$1,473	\$669	\$804
Standard Mounjaro	\$1,746	\$1034	\$712
Standard Rybelsus	\$1,415	\$610	\$805
Standard Trulicity	\$1,560.25	\$876	\$684
Standard Bydureon	\$1,326.29	\$582	\$744

Bluebook Rx Guides Members to Cost Savings

More than one way to achieve high-quality, low-cost results


Key Stat: Drug class changes, while only 23% of total switches, deliver 59% of the financial savings

Personalized Rx savings recommendations



© 2023 Healthcare Bluebook. All Rights Reserved.

Empower your members with data to be better consumers



Healthcare Bluebook

Data supporting the consumer during each step of the care journey





Prescription Advocacy Programs

- Work with manufacturers, doctors, charitable organizations, etc.
- Can help lower costs for patients
- Can work with commercially insured patients
- Typically charge small fee to patient (only if able to save them \$)
- Rx Help Centers is an example



Next Steps for Plan Sponsors to Consider

- ✓ Consult with your broker/consultant
- ✓ What are you doing to solve Rx challenges currently?
- ✓ How are those choices impacting your members ability to navigate their pharmacy benefit?
- ✓ How are they controlling your annual trend?
- ✓ What reporting are you receiving from your PBM to validate member engagement and savings?



Healthcare Bluebook.

THANK YOU!

Panel: Addressing Obesity and Diabetes

Moderator

Katherine Saunders, MD

Obesity Physician, Weill Cornell Medicine, and Co-Founder of Intellihealth

<u>Panel</u>

Anoop Sangha, MD

VP of Clinical Programs, Transcarent

Tracy Sims

Director of Corporate Affairs, Eli Lilly and Company

Tracy Zvenyach, PhD

Director of Policy Strategy and Alliances, Obesity Action Coalition



Optimization of Obesity Care in the Employer Space

Presented by


Katherine H. Saunders, MD, DABOM

Obesity Medicine Physician, Weill Cornell Medicine

Co. Coundar Intellibooltk

Definition of Obesity / Terminology

- A chronic, relapsing, multifactorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences
- "anti-obesity medication" NOT "weight-loss drug"
- "individual WITH obesity" NOT "obese person"



Pic reference: https://www.health.harvard.edu/blog/brain-gut-connection-explains-why-integrative-treatments-can-help-relieve-digestive-ailments-2019041116411

A Large Armamentarium is Necessary to Treat this Complex Disease



The Conversation has Changed from Raising Awareness to COST....



Chronic conditions related to obesity




74% of the population has overweight or obesity & only 4% are being treated.



⊠ Intellihealth

Market Analysis

Anti-Obesity Pipeline



The landscape is growing dramatically.

Many companies are **not yet covering** obesity care for their employees while others have **rescinded coverage** due to overspend.

Is there a <u>middle ground</u> and how do you determine <u>what your employees need</u>?

Innovations in Employer Health/Wellness Benefits

Quick Rounds 6 Innovators for Employer Health

<u>Format</u>

Each speaker will have <u>only</u> 5 minutes to convey their innovative product/service



(We don't have a "stage hook",

so instead, microphone will cut off when time runs out!)






Innovator #1: Ciba Health










Where transformation begins

The Burden of Chronic Disease



¹Includes diabetes, cardiovascular disease, cancer dementia, kidney disease, liver disease, and respiratory disease. ²Includes respiratory infections, road injuries, and tuberculosis Source: Global Burden of Disease, Institute for Health Metrics and Evaluation, Dec 2022

McKinsey & Company


Treating the Root Cause



Symptoms	Root Cause
Diabetes	Inflammation
High Blood Pressure	Stress
Infertility	Poor Diet
Depression	Toxins
Anxiety	Lack of Sleep
Cancer	Unhealthy Relationships
PCOS	Nutrient Deficiencies
High Cholesterol	Lack of Exercise
Irritable Bowel	Negative Thoughts
Autoimmune Disease	Trauma
Chronic Fatigue	Genetics
Hormone Imbalances	Poor Digestion
Thyroid Issues	Lifestyle Choices
Obesity	Side effects of Rx



A Comprehensive Approach



The Ciba Health Advantage

Unlike point solutions, Ciba Health can cater to a variety of organizational needs:

- A stand alone to address specific high cost populations, like those with diabetes and obesity.
- A complement to existing programs for more challenging cases.
- A benefit to all who deserve a higher, more personalized standard of care.



Our Impact

98% chronic disease reversal

75% Program Completion

Below 5.7 All Patients have an A1C Reduction


30lbs Average Weight Loss

78% Oura Sleep Score Improvement

85% Medication Reduction

80 Net Promoter Score (Patient Satisfaction)





ciba health

Thank you!

Nate Cress (651) 285-8868 ncress@cibahealth.com

Innovator #2: Grail

GRAIL





*** Galleri**°



A Breakthrough for Cancer Screening & Overall Employee Health


The Galleri[®] multi-cancer early detection (MCED) test

Lisa Krause - Director of Employer Partnerships



EARLY vs. LATE


Detecting cancer early can dramatically improve 5year cancer survival



"Early/Localized" includes invasive localized tumors that have not spread beyond organ of origin, "Late/Metastasized" includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.

US-GA-2200231-3 CONFIDENTIAL & PROPRIETARY Based on 5-year cancer-specific survival rates. Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50-79 diagnosed 2006-2015. Data on file GA-2021-004

Employees face a health challenge: there are only recommended screenings for ~30% of cancers



Breast - Cervical - Colorectal - Lung (smokers at risk) - Prostate



Incident cancers with USPSTF recommended screening. CGAROA31 June 10 Sector recommended screening.

The Galleri[®] multi-cancer early detection test

Now you can screen for a signal shared by 50+ cancers, with a simple blood draw.¹

The Galleri test is also the #1 employee-ranked health benefit.2*

Recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test looks for a signal associated with active cancer and does not predict future genetic risk for cancer. Galleri should be used in addition to healthcare provider recommended screening tests.

*Market research included 1,000 respondents who were full-time employees working at companies with at least 3000 employees; 15% of sample aged 65+, 70% of sample aged 50-64; 15% aged under 50 with cancer risk factors. Respondents were a representative mix across gender, region, race, ethnicity.

US-GA-2200231-3 CONFIDENTIAL & PROPRIETARY

1: Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. Doi: 10.1016/j.annonc.2021.05.806. 2. Market research data on file GA-2022-0089



126

Galleri was able to detect a signal shared by 50+ cancer types in clinical studies - including 45 cancer types without recommending screening

Breast	Cervical	Colorectal
	Lung	Prostate
Adrenal Cortical Carcinoma Ampulla of Vater	Liver Lymphoma (Hodgkin and Non-Hodgkin)	Plasma Cell Myeloma and Plasma Cell Disorders Small Intestine
Anus	Melanoma of the Skin	Soft Tissue Sarcoma of the Abdomen and
Appendix, Carcinoma	Merkel Cell Carcinoma	Thoracic Visceral Organs
Bile Ducts, Distal	Mesothelioma, Malignant Pleural	Soft Tissue Sarcoma of the Head and Neck
Bile Ducts, Intrahepatic	Nasal Cavity and Paranasal Sinuses	Soft Tissue Sarcoma of the Retroperitoneum
Bile Ducts, Perihilar	Nasopharynx	Soft Tissue Sarcoma of the Trunk and Extremities
Bladder, Urinary	Neuroendocrine Tumors of the Appendix	Soft Tissue Sarcoma Unusual Histologies and Sites
Bone	Neuroendocrine Tumors of the Colon and Rectum	Stomach
Esophagus and	Neuroendocrine Tumors of the Pancreas	Testis
Esophagogastric Junction	Oral Cavity	Ureter, Renal Pelvis
Gallbladder	Oropharynx (HPV-Mediated, p16+)	Uterus, Carcinoma and Carcinosarcoma
Gastrointestinal Stromal Tumor	Oropharynx (p16-) and Hypopharynx	Uterus, Sarcoma
Gestational Trophoblastic Neoplasms	Ovary, Fallopian Tube and Primary Peritoneum	Vagina
Kidney	Pancreas, exocrine	Vulva
Larynx	Penis	
Leukemia The Calleri test does	not detect a signal for all cancers and all cancers cannot be detected	in the blood. Folse positive and folse pogative results do occur

The Galleri test does not detect a signal for all cancers and all cancers cannot be detected in the blood. False positive and false negative results do occur.




https://www.galleri.com/the-galleri-test/types-of-cancer-detected

Klein E, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167 – 1177. Amin MB, Edge S, Greene F, et al. (Eds.). AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017

US-GA-2200231-3 CONFIDENTIAL & PROPRIETARY 127

Cancer benefits have historically been *preventive* or *reactive*, with imperfect adherence rates to recommended screenings



128

The high cost of cancer often occurs in later stages^{1,2} and affects everyone in your organization

Late stage cancer can cost $\sim 3X$ more than early stage cancer³

Employees

Employers

1

In 2018 alone, cancer patients in the U.S. paid \$5.6 billion out of pocket for cancer treatments.⁴ For the first time in the history of BGH's annual health care survey, cancer has overtaken musculoskeletal conditions as the #1 cost driver for employers.⁵




 Based on stage II and stage IV breast, colorectal, and lung cancer, and metastatic/non-metastatic pancreatic cancer. 2. Banegas MP, Yabroff KR, O'Keeffe-Rosetti MC, et al. Medical Care Costs Associated With Cancer in Integrated Delivery Systems. J Natl Compr Canc Netw. 2018;16(4):402-10. 3 Reddy SR, Curr Med Res Opin. 2022;38(8):1285-1294. doi: 10.1080/03007995.2022.2047536.
 <u>https://www.fightcancer.org/sites/default/files/National%20Documents/Costs-of-Cancer-2020-10222020.pdf</u>. Data retrieved from the Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey, 2018. https://meps.ahrg.gov/mepsweb/

5. Business Group on Health. 2023 Large Employers' Health Care Strategy and Plan Design Survey. August 2022. Available at: https://www.businessgrouphealth.org/resources/2023-farge-employers-health-care-strategy-survey-intro

1 @lkrause@grailbio.com consider removing and voicng over in your intro on unmet need _Assigned to lkrause@grailbio.com_ Ailene Bui, 3/12/2024

Galleri is supported by robust clinical data, helping with the #1 ranked medical fear for Americans: cancer¹



The Galleri test does not detect a signal for all cancers. False positive and false negative results do occur.

*The group of cancers responsible for two-thirds of annual US cancer deaths included anus, bladder, colon/rectum, esophagus, head and neck, liver/bile-duct, lung, lymphoma, ovary, pancreas, plasma cell neoplasm, and stomach.

In the Circulating Cell-free Genome Atlas sub-study (CCGA3), a prospective, case-controlled, observational study that included cancer (n=2823) and non-cancer (n=1254) participants without a history of cancer, a Cancer Signal Origin (CSO) prediction accuracy was <u>88.7% for cancer participants with a cancer signal detected</u>


1. MedicareAdvantage.com. What Medical Condition Are You Most Afraid Of?. Published May 5, 2021.2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. Doi: 10.1016/j.annonc.2021.05.806. 3. Amin MB, et al (Eds). AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017.




US-GA-2200231-3 CONFIDENTIAL & PROPRIETARY 130

Health Equity

Helps to address barriers to *access* regardless of location, race, or background: just 1 blood draw, available almost anywhere






"We believe *healthcare is a fundamental right*, and we want to do our part to make sure our people have access to the highest-quality care possible"

- Senior VP, Total Rewards Experience, Paramount



US-GA-2200231-3 CONFIDENTIAL & PROPRIETARY 131

The Galleri test is part of a comprehensive and employee-oriented experience





There are no recommended screenings for ~70% of cancers.

By adding Galleri to recommended screenings, your employees can go further from screening for 5 cancers to screening for 50+.

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests.



Incident cancers with USPSTF A or B recommended screening.

SEER Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50+ diagnosed 2006-2015

https://www.galleri.com/the-galleri-test/types-of-cancer-detected

Klein E, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167 - 1177.

Amin MB, Edge S, Greene F, et al. (Eds.). AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017

United States Preventive Services Task Force (USPSTF) recommended cancer screening.

https://uspreventiveservicestaskforce.org/uspstf/topic_search_results?

GA-2200231-3 CONFIDENTIAL & PROPRIETARY 133

Innovator #3: Transcarent

transcarent








The Employer's Dilemma: By the Numbers



Rising Healthcare Costs

Medical costs will accelerate **7-10%+** in 2024



Benefit Complexity

Most offer 20+ digital health solutions



Inappropriate Cancer Care

11% of people are misdiagnosed




Ballooning Pharmacy Costs

Pharmacy is driving ~20% of healthcare spend



We Are the **One Place** for Health & Care



Connected to employer's existing networks and benefits

Powered by the Transcarent Clinic and National Independent Provider Ecosystem, plus top virtual solutions

HITRUST

CSF Certified

Trusted By Millions of Consumers and Hundreds of Notable Clients

Transcarent is **the only health & care solution** to meet HITRUST CSF, SOC 2 Type 2 and ISO 27001 certifications combined.





Innovator #4: Currax







NCBCH Innovator Presentation

March 15, 2024





Confidential and proprietary. For internal purposes only. Not for promotional use.

ABOUT CURRAX

BRANDED MEDICINES

CURRAX PRODUCT LAUNCH

INTO BILLION \$+ MARKET

PATENTS WORLDWIDE

ROW DISTRIBUTION

PARTNERSHIPS

NUTRACEUTICALS

Consistent

NET SALES

400

12

20+

GENERIC

COST-EFFECTIVENESS

SUMMARY

REFERENCES

Currax is focused on the #1 and #2 preventable deaths in the United States: **smoking* and obesity**

(\overline{s})

HEADQUARTERS Nashville, TN

Operating subsidiary: Orexigen Therapeutics based in Dublin, Ireland




EMPLOYEES[†] **~145** with **~90** in sales/sales leadership and

100+ years of combined leadership experience

*Investigational product under review. †As of January 2024.

INTENDED FOR PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES ONLY.



At Currax, we challenge ourselves to think differently and inspire each other to **enhance the lives of patients** by **improving access** to life-changing medications.



140

When it comes to considering treatments for formulary inclusion for weight management, ONE SIZE doesn't fit all¹


Different obesity phenotypes create unique challenges for weight-loss success

In a recent pragmatic study, individualized treatment approaches based on 4 phenotypes were associated with significantly greater weight loss after 12 months compared with the nonphenotype-quided groups.^{1,*}

STUDY DESIGN +

Obesity (Silver Spring). 2021;29(4):662-671

of patients



HUNGRY BRAIN™, HUNGRY GUT™, EMOTIONAL HUNGER™, and SLOW BURN™ are registered trademarks of Phenomix Sciences.

Reference: 1. Acosta A, et al. Obesity (Silver Spring). 2021;29(4):662-671.

INTENDED FOR PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES ONLY.

Contrave (naltrexone HCI/bupropion HCI) 8 mg/90 mg • Extended-Release Tablets

A chronic weight management option for your adult members

Indication

CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

- 30 kg/m² or greater (obese) or
- 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)

Limitations of Use

The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Suicidality and Antidepressant Drugs

CONTRAVE[®] is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some other antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on CONTRAVE, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. CONTRAVE is not approved for use in pediatric patients.

Please see Important Safety Information on slides 14-18. Please see Full Prescribing Information, including Medication Guide, for CONTRAVE. INTENDED FOR PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES ONLY.



42

ABOUT CURRAX

SUMMARY

19

Consider CONTRAVE to help patients seeking weight loss who struggle with emotional eating^{1,2,*}





CONTRAVE is the only FDA-approved 2-in-1 combination drug containing extended-release (ER) naltrexone and bupropion for patients who are overweight or who have obesity.¹

CONTRAVE has a unique mechanism of action that targets two areas of the brain to give patients more control^{1,3,*}

In the hypothalamus, naltrexone/bupropion work synergistically to curb hunger



*The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood.1

Within the mesolimbic reward system, naltrexone and bupropion regulate feelings of pleasure when eating to help control cravings

FDA=US Food and Drug Administration.

⁺Based on the number of prescription fills for brand-name weight-loss drugs in the IQVIA database, June 2022 to May 2023. **References: 1.** CONTRAVE. Prescribing information. Currax Pharmaceuticals LLC; 2023. **2.** Acosta A, et al. *Obesity (Silver Spring)*. 2021;29(4):662-671. **3.** Greenway FL. *Int J Obes (Lond)*. 2015;39(8):1188-1196.

Please see Important Safety Information on slides 14-18. Please see <u>Full Prescribing Information</u>, including Medication Guide, for CONTRAVE.

INTENDED FOR PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES ONLY.



REFERENCES

The safety of CONTRAVE has been demonstrated across multiple phase 3 clinical trials¹

Adverse reactions reported with ≥4% incidence with CONTRAVE and more commonly than placebo ¹				
ADVERSE REACTION	CONTRAVE (n=2545)	PLACEBO (n=1515)		
Nausea	32.5%	6.7%		
Constipation	19.2%	7.2%		
Headache	17.6%	10.4%		
Vomiting	10.7%	2.9%		
Dizziness	9.9%	3.4%		
Insomnia	9.2%	5.9%		
Dry mouth	8.1%	2.3%		
Diarrhea	7.1%	5.2%		
Anxiety	4.2%	2.8%		
Hot flush	4.2%	1.2%		
Fatigue	4.0%	3.4%		
Tremor	4.0%	0.7%		

- The most frequent adverse reactions leading to discontinuation with CONTRAVE were nausea (6.3%), headache (1.7%), and vomiting (1.1%)
- Common GI-related adverse events, nausea and vomiting, were generally transient in nature and resolved over time (about 2 to 4 weeks)²⁻⁴

GI=gastrointestinal.

References: L CONTRAVE. Prescribing information. Currax Pharmaceuticals LLC; 2023. 2. Greenway FL, et al. Lancet. 2010;376(9741):595-605. 3. Wadden TA, et al. Obesity (Silver Spring). 2011;19(1):110-120.4. Hong K, et al. Clin Obes. 2016;6(5):305-312.

Please see Important Safety Information on slides 14-18. Please see <u>Full Prescribing Information</u>, including Medication Guide, for CONTRAVE.

INTENDED FOR PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES ONLY.



ABOUT CURRAX	DISEASE BURDEN	CONTRAVE	COST-EFFECTIVENE	SS SUMMARY	REFERENCES	
Despite promising weight-loss results from multiple phase 3 trials, CONTRAVE is underutilized at only 3% ¹⁻³ Product Classes					e	
	c	eward System of the Brain Mesolimbic)	Reward System of the Brain (Mesolimbic)	Phentermine Therapies (Amphetamines)	Gastro (GLP-1 & GLP-1 + Helper)	
Phenotypes (% of all s patients)	tudy Emotion 30%	-	Hungry Brain: 40%	Slow Burn: 12%	Hungry Gut: 18%	
Products* *Noncomparative data to phenotypes listed above	:he	VE	Qsymia (DEA CIV)	Phentermine (DEA CIV)	Zepbound Saxenda (QD) Wegovy (QW)	
Factors	Noncont Substan Oral No Risk	ce of Addiction	Amphetamine Class DEA Controlled (CIV) Oral Risk of Addiction	Amphetamine Class DEA Controlled (CIV) Oral Risk of Addiction	Weekly Injectable Daily/Weekly Injectable	
AOM Market Share (% all patients)	of	3%	56%		41%	
Monthly List Price (W	AC)	\$625	Various/Generics		\$1,060-1,349	

Sources: AnalySource WAC pricing; IQVIA National Prescription Audit (NPA), May 2023 actuals and Internal Demand Data.

This is for illustrative purposes only. No comparison, direct or implied, can be made on efficacy between any of these classes.

AOM=antiobesity medication; CIV=schedule 4; DEA=US Drug Enforcement Administration; GLP-1=glucagon-like peptide 1; QD=once a day; QW=weekly; WAC=wholesale acquisition cost. **References: 1.** Apovian CM, et al. 2013;21(5):935-943. **2.** le Roux CW, et al. *EClinicalMedicine*. 2022;49:101436. **3.** Acosta A, et al. *Obesity (Silver Spring)*. 2021;29(4):662-671.

INTENDED FOR PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES ONLY.

PRODUCT NAME		RECOMMENDED MAINTENANCE DOSE	WAC PER PACKAGE	
Contrave (raltrexone K(//buptopion HCl)) BrayBing - Landed Heave Later		Oral tablets, 4 tablets a day (8-mg/90-mg tablet)	\$625.20 (One bottle, containing 120 tablets)	
Xenical® (orlistat)	1,3	Oral capsules, 3 capsules a day (120-mg capsule)	\$650.48 (One bottle, containing 90 capsules)	
Qsymia [®] (phenter extended-release This is a DEA-contr		Oral capsules, once daily (7.5- mg/46-mg capsule)	\$197.16 (One bottle, containing 30 capsules)	
Saxenda® (liraglut	ide) ^{1,5}	Pre-filled injection pen, once daily (3 mg)	\$1,349.02 (Five pen-injectors [syringes])	
Wegovy [®] (semagle	utide) ^{1,6}	Pre-filled injection pen, once weekly (2.4 mg)	\$1,349.02 (Four pen-injectors [syringes])	View cost per QALY
Zepbound™- (tirze	patide) ⁷	Pre-filled injection pen, once weekly (15 mg)	\$1,059.87 (Fourpen-injectors [syringes])	and evLY gained

CONTRAVE[®] is a registered trademark of Currax Pharmaceuticals LLC. All other trademarks are the property of their respective owners. DEA=US Drug Enforcement Administration; evLY=equal value life year; QALY=quality-adjusted life year; WAC=wholesale acquisition cost.

References: 1 AnalySource. WAC price data. Accessed September TI, 2023. 2 CONTRAVE Prescribing information. Currax Pharmaceuticals LLC; 2023. 3. Xenical. Prescribing information. H2-Pharma LLC; 2022. 4. Qsymia. Prescribing information. VIVUS LLC; 2022.
 5. Saxenda. Prescribing information. Novo Nordisk Inc; 2023. 6. Wegovy. Prescribing information. Novo Nordisk Inc; 2023.
 7. Medi-Span Price Rx WAC price data. Accessed January 23, 2024.

Please see Important Safety Information on slides 14-18. Please see <u>Full Prescribing Information</u>, including Medication Guide, for CONTRAVE.

INTENDED FOR PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES ONLY.



← 26 →

28

For adult members who cannot successfully lose weight with lifestyle modification alone, CONTRAVE may help control their cravings and support their chronic weight management¹⁻⁴



CONTRAVE is the only FDA-approved 2-in-1 combination drug containing ER naltrexone and bupropion for patients who are overweight or who have obesity, to give patients more control of their cravings and curb hunger^{1,2,*}



In clinical trials (COR-I and COR-BMOD), CONTRAVE combined with diet and exercise achieved significantly greater weight loss compared with placebo^{1,3,4}



CONTRAVE is generally priced lower than select branded competitors and is cost-effective compared with lifestyle modification alone^{5,6}

-CONTRAVE is **less than** half the cost of most GLP-1s

*The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood.¹

ER=extended-release; FDA=US Food and Drug Administration; GLP-1=glucagon-like peptide 1.

References: 1. CONTRAVE. Prescribing information. Currax Pharmaceuticals LLC; 2023. 2. Greenway FL. Int J Obes (Lond). 2015;39(8):1188-1196. 3. Greenway FL, et al. Lancet. 2010;376(9741):595-605. 4. Wadden TA, et al. Obesity (Silver Spring). 2011;19(1):110-120. 5. AnalySource. WAC price data. Accessed September 11, 2023. 6. Atlas SJ, et al. ICER. Evidence Report. Accessed September 13, 2023.

Please see Important Safety Information on slides 14-18. Please see Full Prescribing Information, including Medication Guide, for CONTRAVE.

INTENDED FOR PAYERS, FORMULARY COMMITTEES, OR SIMILAR ENTITIES ONLY.



Thank you!

CONTACT: Connie Kisinger, MBA Employer Engagement Director ckisinger@curraxpharma.com 913-233-6983





Innovator #5: Quantum Health

Quantum® HEALTH





NO ONE NAVIGATES THEIR HEALTHCARE JOURNEY ALONE

Copyright © 2023 Quantum Health, Inc. - Confidential & Proprietary



Leading the Way in Healthcare Navigation

MOST EXPERIENCED	24 YEARS: FOUNDED THE CATEGORY	18 YEARS OF VALIDATED RESULTS		EEST VORES 500	
THE LARGEST	2.7 MILLION CONSUMERS	1,900 HEALTHCARE WARRIORS [®]	475+ CLIENTS ACROSS INDUSTRIES	GREAT PLACE TO WORK	CINERAL PARTY IN BUSINESS AWARDS 2021
FINANCIALLY STRONG	2+ DECADES PROFITABLE W/ STRONG RESERVES	95% RETENTION RATE		FORTUNE 100 BEST COMPANIES TO WORK FOR	Enc.




NO ONE CHOOSES TO BE A HEALTHCARE CONSUMER

50% PATIENTS CONFUSED


44% HIT A DEAD END AND STOP

24% OF ALL PHYSICIAN SERVICES ARE DUPLICATED **33%** OF PATIENTS NOT GIVEN POST-DISCHARGE INSTRUCTIONS


61% OF SELF-REFERRALS GET IT WRONG, RESULTING IN 33% HIGHER COST



Comprehensive Solutions That Are Consumer-Centric



Simplifying the Experience with a Single Point of Contact



Impact of Real-Time Intercept[®]

MORE INTERACTIONS

MORE SAVINGS

60%

of first contacts are through provider intercepts

83%

of first intercepts are benefits-oriented traditional UM alone will not adequately activate difference in savings when intercepted 4 to 6 months before the catalyst month

12%

lower costs in cases with RTI initiated by a provider inquiry

Quantum

88%


of high-cost claimants

engaged through Real-Time Intercept

RTI[®] Helps Deliver Improved Clinical and Financial Outcomes **Real-Time First Claim** COST Intercept[®] Point Received First interaction occurred 35 days before a claim was **OUTCOMES** received for Marshall RTI **16** INTERACTIONS WITH QUANTUM HEALTH 12 with the provider / 4 with Marshall TIME 3/9 3/10 4/16 Marshall diagnosed Provider called Quantum Health Quantum Health first for surgery benefits; Quantum saw claim in the system Health reached out to Marshall 157 Copyright © 2023 Quantum Health, Inc. – Confidential & Proprietary HEALTH

Delivering more value than an ASO

	Without Quantum Health	With Quantum Health
Member/Provider Services	\square	\checkmark
Pre-Cert/Concurrent/Utilization Review	\square	\checkmark
Case and Chronic Condition Management	\square	\checkmark
Pre-/Postdischarge Management	\square	\checkmark
Maternity Management (high-risk)	\square	\checkmark
Consumer Navigation		\checkmark
Real-Time Intercept®		\checkmark
Advocacy and Provider Selection		\checkmark
Episodic Care Coordination		\square
Point Solution Engagement		\checkmark
Local Pod (clinical and nonclinical co-located)		\checkmark
Member Communication		$ \checkmark$





- Complete navigation and clinical care coordination
- Better employee experience
- **Lower total investment**





Understanding the impact of Quantum Health





Innovator #6: The Lactation Network


THE LACTATION NETWORK





THE LACTATION NETWORK. With over 2,000 clinicians practicing in all 50 states, The Lactation Network (TLN) is the largest network of International Board-Certified Lactation Consultants in the Nation.





Kim Kozeny VP, Strategic Partnerships kkozeny@tln.care

Culture of Wellbeing Award

Kim Davis

Sr. Director HR Operations, Compensation & Benefits Alex Lee, Inc

2022 Culture of Wellness (Large Company Category)





Culture of Wellbeing Award

A statewide award recognizing the best employer wellness & wellbeing programs

First annual award was in 2022 In honor of NCBGH's founder, Chris Coté as the Culture of Wellness Award

> In 2024: Culture of Wellbeing Award to recognize total person health in wellness and wellbeing





Culture of Wellness Award

2023 Winners

City of Charlotte (Large Employer Category)

&


Glen Raven (Small/Midsize Employer Category)

2022 Winners

Alex Lee (Large Employer Category)

&

Cleveland County Government (Small/Midsize Employer Category)





Culture of Wellbeing Award

For 2024, programs were evaluated across 5 primary components:

Culture, Foundation and Policies

- Senior leadership involvement and support
 - Embedment in company culture

Progam Offerings / Tools / Incentives

- Pillars/Dimensions of Health
- Onsite, telephonic, digital (online) programs
 - Rewards for participating/engaging

Strategic Planning / Communications

- Goals and objectives/multi-year strategy
 - Channels of communication

Reporting Metrics & Evaluation

- Means of evaluation
- Observed program engagement

Innovation

• Unique and innovative approaches to wellbeing and program success



2024 Award – Honorable Mention

Honorable Mention

Henderson County (Small/Midsize Category)





Culture of Wellness Award 2024 Winner

NORTH CAROLIN

Clitute of Wellbein

"Ward



Congratulations to

City of Rocky Mount

Chrisie Tyson Wellness Coordinator





Culture of Wellness Award 2024 Winner

JORTH CAROLIN

ESS COALITION OF

Large Employer

Congratulations to

Auard Citute of Wellbeing **Volvo Group North America**

Angie Smallwood Manager – H&W Benefits Strategy





Health For Life Program Objectives



RISK REDUCTION

Ensure we're providing the right behavior change programs for Volvo's employees/spouses to reduce their modifiable risks. R

ENGAGE HARD TO REACH / OPPORTUNITY POPULATIONS

Continued focus on engaging employees in hard-to-reach locations and those who may need additional assistance accessing tools. Spouse engagement will be a focus in 2024.



PARTICIPATION

Encourage employee engagement in the program throughout the year (HA and biometric completion rates, portal/app usage, all coaching modalities, incentives and new internal and vendor partner program offerings).

Health and Financial Wellness Plans



- Managed by WebMD 5 long term onsite Dedicated Wellness Specialist (DWS) located at our largest facilities
- Activities from January December
- Participation rates 40% for Biometric Screenings, Health Assessment and Tobacco Pledge
- Results from screenings/assessments determine programs to be offered throughout the year
- Incentives include reduced medical premiums and/or gift cards.
 Healthy People Rewards up to \$150 if meet thresholds in weight, cholesterol, blood pressure

Financial Wellness Wealth For Life



- Program Launch October 1, 2021
- Financial coaches provide guidance regarding getting out of debt, planning for retirement, paying for college, buying a home, and more.
- A few Webinars hosted by Wealth For Life include:
 - Volvo Group & VCE Pension Change Webinar
 - Getting Financially Fit
 - Pay Cycle Change
 - Inflation What Does it Mean to Me?
 - Funding Your Child's Education
 - Using Your Health Savings Account Effectively
 - Safeguarding Your Finances Online Ways to Protect Your Financial Accounts
 - Kids & Money

Testimonials



Hello, When I came to Volvo a year ago, I was unhealthy and tired. I went through the biometric screening when I came in for insurance cost purposes. I didnt realize just HOW unhealthy I had become. So my healthy lifestyle changed that day... I have lost over 90 pounds. I have been taken off of my blood pressure meds and have more energy than I ever have. My A1C is down significantly (I was on my way to being a diabetic) My BMI is now where it is supposed to be. I will be on this lifestyle change from now ! Being scared and told you are heading towards diabetes, your BP is too high and I had so many aches and pains from being overweight I scared myself! Thank you Health for Life for all of the tips, and sharing of information to get healthy and encouragement to stay healthy!

I found during a biometric screening I had high blood pressure, very high blood pressure. I went on medication but also decided to change my lifestyle by improving how I eat and exercise. This change lowered my blood pressure and weight by 50 pounds. I now feel better than I had in years, and I am very energetic now too. I am so glad I found this out before it became a long-term issue causing detrimental impact to my health. If you have not done a screening, I would recommend it so you can know your overall health. Take action before it is too late.





13403 Volvo Way Hagerstown, MD 21742 (240) 500-3764





Family Health Center 4881 Cougar Trail Road Dublin, VA 24084

- Full-service primary care, certified as a Patient Centered Accredited Home
 - Includes Primary Care, Behavioral Health, Nutrition Services, Physical Therapy
- Full-service pharmacy operated by Walgreens
- Eligibility includes Full Time Active Employees covered under the medical plan and covered dependents age 2 and older
- 61.6% Unique Employees Utilizing; 1,941 Unique Members
- Variable Copay Program began 2022 \$365,758 savings

- Full-service primary care
 - Includes Primary Care, Nutrition Services, Chiropractic Services, Physical Therapy
- Full-service pharmacy operated by A-S Medications Solutions
- Eligibility includes Full Time Active Employees covered under the medical plan and covered dependents age 2 and older
- 92% Provider Capacity; 63.6% Unique Employees Utilizing; 2,619 Unique Members

2024-03-18

Employee Resource Groups



Caregivers Network (CGN)



Early Career Professionals Network (ECPN)



Professional Women's Network (PWN)



Women in Engineering




V-Eagle (Global)

New ERGs recently added:

- Veteran's, Military & Military Spouses
- Neurodivergence & Physical Disabilities
- Black Employees Resource Group

EAP & Advocacy



2024-03-18

Voluntary Benefits



Point Solutions



Workplace Mental Health Strategy Architecting for Performance Excellence



Michael Thompson

Board Member, Outcome Referrals, Inc

Past CEO, National Alliance of HC Purchaser Coalitions



Workplace Mental Health Strategy Architecting for Performance Excellence

North Carolina Business Coalition on Health Michael Thompson <u>Mjthompson56@gmail.com</u>

National Alliance Mental Health Initiative



National Alliance of Healthcare Purchaser Cealitions Driving Health. Equity and Value PATH FORWARD

Behavioral Health Vendor Engagement Template






Agenda

- Background
- Assessing Progress of the last Decade
- Setting the Stage for the next Decade
- Final tips & takeaways
- Open Discussion

Employer Perspective – Where are we today?

What are your current priorities in your overall mental health strategy?

What are your current challenges to addressing the mental health of your workforce?




- □ When treatment is provided, little accountability for the quality of that treatment.
 - Measurement-based Care is the new standard
 - Required as part of Collaborative Care models
- **One out of five Americans need help but 60% of them do not seek it**
 - Stigma remains a key issue
 - Parity removed benefits disparities but affordability still an issue
 - Benefit plans have implemented high deductibles in-network and even higher cost sharing out-of-network
- □ While better medications are available today, they can be expensive and efficacy can vary individual to individual.
 - Lack of Value Based Formulary
 - First fail rate can be high and costly

Our Current MH Systems of Support



The Evolving Science of Mental Illness



Economics of Stress

- Demands & Pressures are "Additive & Cumulative"
- Coping Skills (resilience)
 predict 16% of outcomes
- Demands & pressures predict 60% of outcomes

Source: Lyle Miller, PhD, Boston University


Internal Efforts Improved Particularly During Pandemic

- Focus
- Access
- Connectivity


- □ Many companies offer an Employee Assistance Program
 - Programs are often "passive" and "crisis focused"
 - Not focused on improving the emotional health of the organization
 - The utilization of these services very low compared to the potential need.
- The provider networks often reflect low participation rates by mental health professionals
 - 55% of the psychiatrists accept insurance vs 88% of physicians in other medical specialties.
 - Concerns include reimbursement and administrative burdens
 - Primary care providers make 20% more for same services as MH professionals
- □ Exacerbated by provider shortages and "phantom networks"
 - The nation needs to add 10,000 providers to each of seven mental health professions by 2025 to meet the expected growth in demand
 - Potentially misleading network providers with long waiting times for appointments and a limited willingness to take on new patients.

Our Current MH Systems of Support

BH Quality Essential but Uneven



Source: 2023 National Alliance Voice of the Purchaser Survey



Bad Situation Getting Better



Best of Times Science & Treatment Mental Health Parity Growing Acceptance


Worst of Times Stigma & Prejudice Access & Quality Stress & Isolation

Workplace Mental Health Path Forward

Know the Impact Break the Silence Affordable, Quality, Integrated Support Culture of Well-being

> Holistic Mental Health & Well-being

Behavioral Health Integration Framework (for Past Decade)



□ Know the Impact

Break the Silence

□ Improve Access to Affordable, Quality Support

□ Move to Culture of Wellbeing





Our Progress in Moving Forward

Depression alone has economic cost of 200 billion dollars

- Most of cost related to persons not able to perform as effectively at work.
- Mental illness is the leading cause of disability in the workforce.

Suicide rates in the United States up 25% from 1999 to 2014

• Largest percentage increase with men and women aged 45-64.

The opioid epidemic is now contributing to overdose being the leading cause of accidental death in the U.S.

• The overdose death rate in 2008 was nearly four times the overdose death rate in 1999.

Growing evidence that loneliness and social isolation are health risk factor on a par with smoking

- Equivalent to smoking 15 cigarettes a day
- Growing concerns that trends in our society and workforces may be increasing these risk factors

Know the Impact

MENTAL HEALTH CRISIS

Ninety percent of the public think there is a mental health crisis in the United States today

90%

One-third of all adults report that they have felt anxious either always or often in the past year

33%

One-third of respondents could not get the mental health services they needed

33%

2022 survey conducted by the Kaiser Family Foundation and CNN



Corporate programs to promote acceptance/readiness

- DuPont, American Express, EY
- ICU, We Care, Right Directions, I Will Listen, Stamp Out Stigma
- Organizational Readiness eg MH First Aid
- Employee Resource Groups

Talk about mental health as a natural extension of overall health

- Create the opportunity for people to speak up about the issues that matter in their lives and for others to offer support before it is apparent or even needed.
- Educate HR and supervisors on how to deal with employees with issues
- Reinforce a culture of an organization that cares about its people and is working to be supportive, inclusive, and engaging.

Employee Resource Groups

Break the Silence



Action Brief



HOPE AND HEALING FOR MENTAL ILLNESS IS POSSIBLE Accountable, Accessible, Affordable Care

ere is no health without mental health; mental health is too vortant to be left to the professionals alone, and mental health is mone's husingese " _ Dr. Vilerum Patel

And an in Adult in State in St

** — Dr. Viewar, Partel

almonts combined."

ins in other medical specializer. Former iculty in finding in-network Former isalth providers extends to Institute Require efforts to measure and improve access and quality of mental health services being provided.

- Assess out-of-network usage and in-network access
- Promote & reimburse for collaborative care in the primary care

Deploy emerging technologies


- Telehealth services as a supplemental access point
- Cognitive behavioral therapy, mindfulness, resilience
- Prescription digital therapies
- Consider pharmaco-genomics to better match medication with the patient and reduce emotional/financial costs of poor quality
 - Early results decrease in Rx (17%), ER (41%), Outpatient (17%), Inpatient (50-60%)

Connect to community resources for consumers & families

• More informed and engaged advocates for care they or their family members need.

Improve Access to Affordable, Quality Support

The Impact of Mental Health Interplay between Mental Health & Overall Wellbeing



Thriving in All Wellbeing elements compared to thriving in Physical Wellbeing only

- 41% fewer unhealthy days
- 2X as likely to say they always adapt well to change
- 36% more likely to say they always fully bounce back after an illness
- 65% less likely to be involved in a workplace accident
- 81% less likely to look for a new job when the job market improves

Source: Gallup Wellbeing Index

Move to a Culture of Wellbeing

Connectivity – A Key to Better Health, Well-being, Engagement & Belonging

Environmental factors are increasing loneliness and isolation

- Geographic "migration" driven by economic and lifestyle factors
- "Diversity polarization" based on race, gender, sexual preferences
- Social media and the "connectivity paradox"

If unrecognized and unaddressed, a "triple-bottom line" issue:

- Physical and mental health impairment adds to benefit costs and reduces productivity
- Reduces ability to collaborate effectively and to engage with customers and co-workers
- Works against creating a "diversity friendly" environment

Source: Jeremy Nobel, MD, MPH, The UnLoneliness Project



Loneliness is more prevalent than once thought...

- 65% ever experienced significant loneliness
- 50% experience loneliness in public lives
- 35% are currently feeling lonely

Importance of Mental Health as Part of Organization's Health Management Strategy

> -35% Highly Important -43% Important


"The mental health of our employees is directly linked to the overall performance of our organization."

- 55% Strongly Agree
- 44% Agree


2022 National Alliance Mental Health Survey

Barriers/Challenges to Addressing Mental Health

November 2022 National Roundtable Survey



What barriers limit access to mental health care for underserved communities?




Foundational concepts such as belonging, inclusion and feeling valued should be considered when developing an overall healthcare strategy

Source: 2023 National Alliance Mental Health & Equity Learning Collaborative


199

Would levels of satisfaction & performance be same if viewed through a Health Equity (subpopulation) lens?



Source: 2022 National Alliance Mental Health Voice of the Purchaser Survey

Next Generation Mental Health – A Whole Person Health Approach



Applies to Multiple Areas

- Wellness interventions
- Prevention/Preventive benefits
- Chronic disease interventions
- Advanced Primary Care
- Episodes of Care
- Care/Case Management
- Advocacy or Navigation Support
- Health Literacy
- Others...

Whole Person Health strategic interventions have outperformed (clinically and financially) efforts that have been more one-dimensional

Developing a Maturity Mindset for Equity

Foster an equitable strategy that is inclusive and supportive by enhancing a level of "cultural competence" and "cultural humility"

- Cultural competency refers to having *a basic understanding of different cultures, norms, and behaviors* to effectively interact with
 diverse groups
- **Cultural humility**, on the other hand, involves a more introspective approach, acknowledging one's *limitations*, *listening to employees' unique experiences and adapting strategies to needs*




(C) 2023 National Alliance of Healthcare Purchaser Coalitions

Newest Frontier in Behavioral Health -Personalized Quality & Provider Matching

Slides Excerpted from Outcome Referrals, Inc.

The \$300B behavioral health crisis



Like rock, paper, scissors, solutions are trumped by the next problem

2

3

1 Until we reward clinicians to return to the market, access won't be solved

- Until we solve the quality problem, it's not cost effective to pay clinicians more
- Quality has been intractable. NIH has wasted 10s of billions trying to find bio-markers and improving treatments



204

problem

Finding good care is a crapshoot because everyone is guessing

Guess #1

At intake, patients are asked to state their treatment needs.

It's the only medical field where patients are asked to diagnose themselves.

Guess #1 b

<u>Patients</u> are screened for depression with PHQ.

50% false positive rate.



Guess #2

<u>Therapists</u> list what they're good at.


Research shows therapists are very poor at identifying their clinical strengths.

(Constantino et al., 2023)



205 crapshoot

Best-practices are more comparable to placebo than a cure



206 placebo care

TOP Match™ eliminates the guesswork



Assess each patient's unique clinical needs

• Our test is one-of-a-kind: we factor analyzed all diagnostic symptoms on millions of patients across all levels of care

• As a result, TOP has unparalleled construct and predictive validity (e.g., Kraus et al, 2005)

Assess provider skills

- · Risk-adjusted patient outcome data from TOP provides an evolving scorecard
- The last 30 clients best predict provider success with his/her next patient (Kraus et al, 2016)



2

Assign the right provider

- There is no change in how providers practice and no additional work required
- Dropout and no-show rates significantly decrease



Redefining exceptional outcomes

Doubles population outcomes and quintuples the number of patients that return to full health and productivity without relapse (Constantino et al, 2021)



case assignment

207

1

Assess clinical needs

7-minutes to actionable insights // Linda's TOP

MPOPTAWL Before answering any question, please read the message of the barry spacing the purposes of all set of the information. Set of the start to be the cost of the information. ENGLISH	DOMAIN	SCORES:
	Depression	
	Poor Life Quality	
 ○ ○ ○ ○ ○ bad alghtmares ○ ○ ○ ○ ○ ○ ○ ○ awakened frequently fouring the night ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ bad trovible retruining to sleep after awakening in the night 	Mania	
□ ○ ○ ○ ○ □ bad a paying-job □ ○ ○ ○ □ bad conflicts with others at work or school frequetiless of finit □ ○ ○ ○ ○ □ bad conflicts with others at work or school for any resson □ ○ ○ ○ ○ □ bad conflicts with others at work or school for any resson	Panic Issues	
○ ○	Reality Testing/Psychosis	
○ ○	Substance Abuse	
0 0	Social Conflict	
••• ••	Sexual Functioning Issues	
○ ○	Sleep Problems	
□ ○ ○ ○ folds grady □ ○ ○ ○ folds reades		
0 0	Suicidality	
	Violence	
	School/Work Functioning	
 ○ ○ ○ ○ ○ ○ 6 felt someone or something was controlling your mind ○ ○ ○ ○ ○ 0 spent more time dinking or using drugs than you intended ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ □ epjected school, work, or other responsibilities because of using alcohol or drugs 		0 1 2 3 4 5 6
\chi \chi \chi \chi \chi \chi \chi \chi		
Provider Code Primary Dx Provider Code Constant Second State Code Constant Second State Code Constant Second State Code Constant Second State Code Code Code Code Code Code Code Cod		

60. E

Predictive Validity

The only tool that can identify clinicians' strengths (96% vs 7%, c.f., Kraus et al, 2011 v <u>Owen et al, 2019</u>)

The only tool that can predict **best provider** match and proven in a double-blind randomized clinical trial (Constantino et al, 2021)

The only tool that can predict future **hospitalizations** as proven with BCBS MA claims analysis 2008. "4x more accurate than our previous models" – Dr. Simmons, BCBSMA Medical Director

The only tool that can predict right **level of care** resulting in 4x more patients achieving above average risk-adjusted outcomes (Trudeau et al. 2023)

Construct Validity

8 9

6 7


The only multi-dimensional outcome assessment with construct validity (c.f., Kraus et al, 2005, 2010). Unlike the PHQ 9 with a poor 50% false positive rate in screening for depression, TOP measures depression and all the other dimensions with **precision**.



208

O Case-Mix form is atta

needs





Our AI systems generate scorecards on clinicians

No one is above on all domains

10% can be classified as "super shrinks"

2% are unable to be scientifically matched

4% of clinicians think they are above in a below domain




There are many <u>A+ TOP Matches</u>: who are statistically "above" their peers on Linda's primary area of need ("panic")






4 Identifying the cure for most BH issues



210 proof

The fastest and easiest way to find your cure



Monitor wait times 5 Accept appointment 6 David R. Kraus, PhD

3

4

President and Chief Science Officer dkraus@outcomereferrals.com

Receive invitation

7-minute assessment

Review TOP Matches

Select favorites

(508) 834-7323 x121



Express Access

The Key is to Design for and Move Upstream to improve:

Affordable and Effective Behavioral Health Support

Our Collective Mental Health and Well-being

Improved Acceptance & Access of Behavioral Healthcare

Aligned Organizational and Individual Well-being

Quality Behavioral Services Matched to Needs of Individual



The key is solving for the "and" not the "or"

Final tips & takeaways

- Confidently and Consistently Connect Mental Health to Your Business Outcomes – Make it Real!
- Integrate a Whole Person Focus including Mental Health across your strategic health & wellbeing spectrum
- Raise your Bar on Accountability for Access, Quality & Outcomes with Greater Focus on "Matching"
- Move Upstream to Improve Connectivity, Integrate Organizational Support and Address Systemic Dysfunction
- Use Data to Understand Blind Spots and Personalize Support to "meet people where they are at"

"Someone is sitting in the shade today because someone planted a tree a long time ago." - Warren Buffett

Questions/ Comments?

Mike Thompson 973-464-1530 mjthompson56@gmail.com

